The present invention provides pharmaceuticals for the prevention or treatment of diseases associated with decrease in tear. That is, the present invention provides pharmaceuticals for the prevention or treatment of diseases associated with decrease in tear such as dry eye, dry disorders of cornea and conjunctiva, disorders of the keratoconjunctival epithelium, syndrome with decrease in tear secretion, xerophthalmia, dry eye due to aging, opthalmopathy in Stevens-Johnson syndrome, opthalmopathy in Sjogren's syndrome, keratoconjunctival ulcer, dryness in wearing of contact lens or the like, which comprises a .beta..sub.3 adrenoceptor stimulant. The present invention also provides a combination pharmaceutical comprising a .beta..sub.3 adrenoceptor stimulant and a .beta..sub.2 adrenoceptor stimulant.